COMPASS THERAPEUTICS, INC.
80 Guest Street
Suite 601
Boston, Massachusetts 02135
September 4, 2024
Via EDGAR Transmission
United States Securities and Exchange Commission
Division of Corporation Finance
100 F Street, N.E.
Washington, D.C. 20549
Re: | Compass Therapeutics, Inc.: Registration Statement on Form S-3 filed August 30, 2024 (File No. 333-281891) |
Ladies and Gentlemen:
Pursuant to Rule 461 under the Securities Act of 1933, as amended (the Act), Compass Therapeutics, Inc. (the Company) hereby requests that the effective date of the above-referenced registration statement (the Registration Statement) be accelerated to September 6, 2024, at 4:01 pm Eastern Time, or as soon thereafter as practicable, unless we or our outside counsel, Goodwin Procter LLP, request by telephone that such Registration Statement be declared effective at some other time. In making this acceleration request, the Company acknowledges that it is aware of its responsibilities under the Act.
If you have any questions regarding this request, please contact Finnbarr Murphy of Goodwin Procter LLP at (212) 459-7257.
Sincerely, |
Compass Therapeutics, Inc. |
/s/ Thomas Schuetz |
Thomas Schuetz |
Chief Executive Officer |
cc: | Thomas Schuetz, Compass Therapeutics, Inc. |
Jonathan Anderman, Compass Therapeutics, Inc.
Richard Hoffman, Esq., Goodwin Procter LLP
Finnbarr Murphy, Esq., Goodwin Procter LLP